Zinman, Bernard

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 376

Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease

Mazer, C. D., Hare, G. M. T., Connelly, P. W., Gilbert, R. E., Shehata, N., Quan, A., Teoh, H., Leiter, L. A., Zinman, B., Jüni, P., et al. (2020) · Circulation

Erythropoietin and Anemia TreatmentDiabetes Treatment and Management

Cited by 371

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Rosenstock, J., Marquard, J., Laffel, L. M., Neubacher, D., Kaspers, S., Cherney, D. Z., Zinman, B., Skyler, J. S., George, J., Soleymanlou, N., et al. (2018) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 363

Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial

Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators (2016) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 347

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trials

Ratner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 346

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes

Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 336

Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study

Molitch, M. E., Steffes, M., Sun, W., Rutledge, B., Cleary, P., de Boer, I. H., Zinman, B., Lachin, J., & for the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Group (2010) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Management and Research

Cited by 306

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial

Mahaffey, K. W., Jardine, M. J., Bompoint, S., Cannon, C. P., Neal, B., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., et al. (2019) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 291

The Effect of Excess Weight Gain With Intensive Diabetes Mellitus Treatment on Cardiovascular Disease Risk Factors and Atherosclerosis in Type 1 Diabetes Mellitus: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) Study

Purnell, J. Q., Zinman, B., & Brunzell, J. D. (2013) · Circulation

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 267

Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER

Shaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., et al. (2022) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 255

Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT

Kahn, S. E., Lachin, J. M., Zinman, B., Haffner, S. M., Aftring, R. P., Paul, G., Kravitz, B. G., Herman, W. H., Viberti, G., Holman, R. R., et al. (2011) · Diabetes

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 249

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

Nicholls, S. J., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N., et al. (2024) · American Heart Journal

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 248

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

Fitchett, D., Butler, J., van de Borne, P., Zinman, B., Lachin, J. M., Wanner, C., Woerle, H. J., Hantel, S., George, J. T., Johansen, O. E., et al. (2018) · European Heart Journal

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 242

Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): A double-blind randomised controlled study

Zinman, B., Harris, S. B., Neuman, J., Gerstein, H. C., Retnakaran, R. R., Raboud, J., Qi, Y., & Hanley, A. J. (2010) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 235

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics

Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., et al. (2017) · American Journal of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 234

Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes

Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D., Nauck, M. A., et al. (2025) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 223

Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

Kraus, B. J., Weir, M. R., Bakris, G. L., Mattheus, M., Cherney, D. Z. I., Sattar, N., Heerspink, H. J. L., Ritter, I., von Eynatten, M., Zinman, B., et al. (2021) · Kidney International

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 219

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA ® )

Marx, N., Rosenstock, J., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Espeland, M. A., Bluhmki, E., Mattheus, M., Ryckaert, B., et al. (2015) · Diabetes and Vascular Disease Research

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 212

Exercise in individuals with IDDM

Wasserman, D. H., & Zinman, B. (1994) · Diabetes Care

Diabetes Management and ResearchPhysical Activity and Health

Cited by 210

Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME Trial

Wanner, C., Heerspink, H. J. L., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., Hantel, S., Woerle, H.-J., Broedl, U. C., von Eynatten, M., et al. (2018) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 209

Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.

Nørgaard, C. H., Friedrich, S., Hansen, C. T., Gerds, T., Ballard, C., Møller, D. V., Knudsen, L. B., Kvist, K., Zinman, B., Holm, E., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions

Diabetes Treatment and ManagementDementia and Cognitive Impairment Research

Cited by 206

Glucose Intolerance in Pregnancy and Postpartum Risk of Metabolic Syndrome in Young Women

Retnakaran, R., Qi, Y., Connelly, P. W., Sermer, M., Zinman, B., & Hanley, A. J. G. (2010) · The Journal of Clinical Endocrinology & Metabolism

Gestational Diabetes Research and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 190

The impact of diabetes on survival following breast cancer

Lipscombe, L. L., Goodwin, P. J., Zinman, B., McLaughlin, J. R., & Hux, J. E. (2008) · Breast Cancer Research and Treatment

Metabolism, Diabetes, and CancerCancer Risks and Factors

Cited by 176

Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial

Buse, J. B., Bain, S. C., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Pratley, R. E., Linder, M., Monk Fries, T., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 175